RESUMO
<p><b>BACKGROUND AND OBJECTIVE</b>Endothelial progenitor cells (EPCs) play an important role in hypoxia-triggered tumor vasculogenesis. However, the homing of exogenous EPCs in tumors is still unclear. In this study, we investigated the recruitment of exogenous EPCs in human lung adenocarcinoma model of nude mice.</p><p><b>METHODS</b>EPCs labeled with green fluorescence protein (GFP) were transplanted into nude mice bearing human lung adenocarcinoma. The growth of tumor was observed. After the mice were killed, GFP-EPCs in different tissues were examined by fluorescence. The tumor tissues were stained for CD133, hypoxia-inducible factor-1alpha (HIF-1α), stromal cell-derived factor-1α (SDF-1α), and vascular endothelial growth factor receptor (KDR). Real-time polymerase chain reaction of CD133, HIF-1α, SDF-1α, and VEGF-1 were also performed.</p><p><b>RESULTS</b>The growth of tumor in EPC group was significantly faster than that in saline solution group (P <0.05). Under fluorescence microscope, GFP-EPCs were strongly expressed in both tumor and bone marrow. EPCs were recruited to the tumor periphery to participate in tumor vasculogenesis. The expression of CD133, HIF-1α, and SDF-1 mRNA in tumor and bone marrow were significantly higher than that in the liver, spleen, and skin (P<0.05).</p><p><b>CONCLUSIONS</b>Exogenous EPCs can be recruited to tumor and accelerate tumor growth. Except tumor, bone marrow can also recruit EPCs.</p>
Assuntos
Animais , Feminino , Humanos , Camundongos , Antígeno AC133 , Adenocarcinoma , Metabolismo , Patologia , Antígenos CD , Genética , Metabolismo , Medula Óssea , Metabolismo , Patologia , Linhagem Celular Tumoral , Quimiocina CXCL12 , Genética , Metabolismo , Células Endoteliais , Patologia , Transplante , Glicoproteínas , Genética , Metabolismo , Proteínas de Fluorescência Verde , Metabolismo , Subunidade alfa do Fator 1 Induzível por Hipóxia , Genética , Metabolismo , Neoplasias Pulmonares , Metabolismo , Patologia , Camundongos Nus , Transplante de Neoplasias , Neovascularização Patológica , Peptídeos , Genética , Metabolismo , RNA Mensageiro , Metabolismo , Transplante de Células-Tronco , Células-Tronco , Patologia , Transfecção , Carga Tumoral , Fator A de Crescimento do Endotélio Vascular , Genética , MetabolismoRESUMO
<p><b>OBJECTIVE</b>To investigate the feasibility and short- term effect of injecting botulinum toxin A through anorectum to treat Hirschsprung disease.</p><p><b>METHODS</b>Eight cases with Hirschsprung disease were proven pathologically or diagnosed by barium enema. At the clock point of 3,6,9 under supine posture,a total dose of 1.5 U/ kg of botulinum toxin A was injected into the internal anal sphincter and the submucosa of rectum. The pressure of anus- rectum was measured before operation and 1 month,1 year after operation,respectively. Barium enema examination was carried out within 3-6 months after operation,then once a year during followed- up.</p><p><b>RESULTS</b>All of the patients recovered well without operative or postoperative complications. In the first year,all patients could defecate spontaneously without constipation and abdominal distention. Three cases had constipation again and slight abdominal distention 1 year after operation,but the symptoms were relieved after anus dilatation. The resting pressure of anus- rectum was lower 1 month after operation than that before operation (P< 0.01) in 8 cases,and still lower 1 year after operation (P< 0.05)in 6 cases. Barium enema examination within 3-6 months after operation revealed that the dilated colon shrank.</p><p><b>CONCLUSION</b>Botulinum toxin A injection is a new,feasible and safe method for Hirschsprung disease,but the long- term efficacy needs to be further studied.</p>
